Effects of betaine on lipopolysaccharide-induced memory impairment in mice and the involvement of GABA transporter 2 by Miwa, Masaya et al.
RESEARCH Open Access
Effects of betaine on lipopolysaccharide-induced
memory impairment in mice and the
involvement of GABA transporter 2
Masaya Miwa
1, Mizuki Tsuboi
2, Yumiko Noguchi
2, Aoi Enokishima
2, Toshitaka Nabeshima
2 and
Masayuki Hiramatsu
1,2*
Abstract
Background: Betaine (glycine betaine or trimethylglycine) plays important roles as an osmolyte and a methyl
donor in animals. While betaine is reported to suppress expression of proinflammatory molecules and reduce
oxidative stress in aged rat kidney, the effects of betaine on the central nervous system are not well known. In this
study, we investigated the effects of betaine on lipopolysaccharide (LPS)-induced memory impairment and on
mRNA expression levels of proinflammatory molecules, glial markers, and GABA transporter 2 (GAT2), a betaine/
GABA transporter.
Methods: Mice were continuously treated with betaine for 13 days starting 1 day before they were injected with
LPS, or received subacute or acute administration of betaine shortly before or after LPS injection. Then, their
memory function was evaluated using Y-maze and novel object recognition tests 7 and 10-12 days after LPS
injection (30 μg/mouse, i.c.v.), respectively. In addition, mRNA expression levels in hippocampus were measured by
real-time RT-PCR at different time points.
Results: Repeated administration of betaine (0.163 mmol/kg, s.c.) prevented LPS-induced memory impairment. GAT2
mRNA levels were significantly increased in hippocampus 24 hr after LPS injection, and administration of betaine
blocked this increase. However, betaine did not affect LPS-induced increases in levels of mRNA related to inflammatory
responses. Both subacute administration (1 hr before, and 1 and 24 hr after LPS injection) and acute administration (1 hr
after LPS injection) of betaine also prevented LPS-induced memory impairment in the Y-maze test.
Conclusions: These data suggest that betaine has protective effects against LPS-induced memory impairment and
that prevention of LPS-induced changes in GAT2 mRNA expression is crucial to this ameliorating effect.
Background
Betaine (glycine betaine or trimethylglycine) is widely
distributed in plants and microorganisms as well as in
various dietary sources [1,2]. Some plants accumulate
high levels of betaine in response to abiotic stress, and
both exogenous application of betaine and the introduc-
tion via transgenes of the betaine-biosynthetic pathway
into plants that do not naturally accumulate betaine
increase the tolerance of these plants to various types of
abiotic stress, such as drought, high salinity, and tem-
perature stress [3].
In humans, betaine is obtained from the diet [2] or
from its metabolic precursor choline [4]. Betaine is uti-
lized as a methyl donor in a reaction that converts
homocysteine into methionine via betaine-homocysteine
methyltransferase. Betaine also plays a role in osmotic
regulation in the kidneys, which are routinely exposed
to high extracellular osmolarity during normal operation
of the urinary concentrating mechanism [5]. Further-
more, dietary betaine suppresses the activation of
nuclear factor-B (NF-B) with oxidative stress, and the
protein expression of proinflammatory molecules such
as cyclooxygenase-2 (COX-2), inducible nitric oxide
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aged rat kidneys [6,7].
Betaine/GABA transporter-1 (BGT-1), the mouse
transporter homologue of which is known as GABA
transporter 2 (GAT2), is an integral membrane trans-
porter capable of utilizing both betaine and GABA as
substrates [8,9]. The distribution pattern of GAT2
mRNA does not closely match that of GABAergic path-
ways [8]. In a culture study, Olsen et al. [10] suggested
that astroglial GAT2 expression and function are regu-
lated by hyperosmolarity. Zhu & Ong [11] reported that
BGT-1 expression is upregulated after kainite-induced
neuronal injury in rat hippocampus. These reports sug-
gested that GAT2/BGT-1 plays a role in osmoregulation
in neural cells and that upregulation of GAT2/BGT-1
expression contributes to astrocytic swelling after brain
injury. Interestingly, since GAT2 is co-localized with P-
glycoprotein, a blood-brain barrier (BBB)-specific mar-
ker, in brain capillaries [12], it may also be involved in
betaine transport across the BBB. These data suggest
that betaine attenuates inflammatory processes and/or
oxidative stress; however, the effects of betaine on cen-
tral nervous system function in animals are poorly
understood.
Lipopolysaccharide (LPS), a component of the cell wall
of Gram-negative bacteria, is used to experimentally
induce memory impairment, neuroinflammatory
responses, and oxidative stress such as increases in
mRNA levels of interleukin (IL)-1ß and IL-6 [13], heme
oxygenase-1, microglial activation [14], and iNOS activ-
ity in hippocampus [15]. As neuroinflammation and oxi-
dative stress are critical components of the pathogeneses
of some neurodegenerative disorders, including Alzhei-
mer’s disease [16-18], and induce learning and memory
impairment in rats [14], it is important to elucidate
whether betaine improves LPS-induced memory impair-
ment in order to understand the mechanism of action
of betaine in the central nervous system.
In this study, we investigated the effects of betaine on
LPS-induced memory impairment using the Y-maze and
novel object recognition tests. We also examined the
effect of betaine on LPS-induced changes in mRNA
expression levels of proinflammatory molecules, glial
markers, and GAT2 using real-time RT-PCR.
Methods
Animals
Male ddY strain mice (7-9 weeks old, 26 g - 44 g;
Japan SLC., Hamamatsu, Japan) were used. The mice
were kept in a regulated environment (24 ± 1°C, 55 ±
5% humidity) under a 12-h light/dark cycle (lights on
7:45 a.m.) and given food and tap water ad libitum.
The experimental protocols concerning the use of
laboratory animals were approved by the animal ethics
board of Meijo University and followed the guidelines
of the Japanese Pharmacological Society (Folia Pharma-
col. Japon, 1992, 99: 35A); the Interministerial Decree
of May 25th, 1987 (Ministry of Education, Japan); and
the National Institutes of Health Guide for the Care
and Use of Laboratory Animals (NIH Publications No.
8023, revised 1978). All efforts were made to minimize
animal suffering and to reduce the number of animals
used.
Drugs
Betaine hydrochloride (betaine; Sigma, St. Louis, MO,
USA) was dissolved in 0.9% saline and injected subcuta-
neously (s.c.). Lipopolysaccharide from Escherichia coli
0111:B4 (LPS; Sigma) was dissolved in 0.9% saline and
administered intracerebroventricularly (i.c.v.) into the
lateral ventricle of the mouse brain according to the
method of Haley & McCormick [19] at a dose of 5 μL/
mouse under brief ether anesthesia. I.c.v. injections of
LPS or saline were delivered at a rate of 5 μL/15 sec
and injection needles were left in place an additional 10
sec. The total injection volume into the lateral ventricle
was based on previous reports [13] and we confirmed
that there are no influences of i.c.v. injection of saline (5
μL) itself on mouse behavior. The sham control animals
were administered the vehicle (i.c.v. and s.c.) instead of
one of the drug solutions.
Experimental schedules
First, we investigated whether betaine alleviated LPS-
induced memory impairment using the Y-maze and
novel object recognition tests, which were carried out
7 and 10-12 days after the LPS injection (30 μg/
mouse, i.c.v.), respectively. Time schedules of beha-
vioral experiments were referred to a previous report
[15], which showed that LPS-induced memory impair-
ment persists at least 15 days after LPS injection. To
investigate the effects of repeated administration of
betaine, mice were continuously treated with betaine
(0.081, 0.163, or 0.326 mmol/kg, s.c.) for 13 days start-
ing 1 day before LPS injection. On the day of the
tests, betaine was administered 30 min before the start
of the tests (Figure 1A). Proinflammatory molecules
and glial activation are important for the pathogenesis
of LPS-induced memory impairment, so we measured
LPS-induced changes in mRNA expression of proin-
flammatory molecules and glial markers. The expres-
sion of each mRNA was measured 6 hr
(proinflammatory molecules) or 24 hr (glial markers
and betaine transporter) after LPS injection (Figure
1A). To investigate the effects of subacute administra-
tion of betaine, mice were treated with betaine (0.163
mmol/kg, s.c.) 1 hr before, 1 and 24 hr after LPS
injection (Figure 1B).
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Immediate working memory was assessed by recording
spontaneous alternation behavior during a single session
in a Y-maze [20] made of black painted wood. Each arm
was 40 cm long, 12 cm high, 3 cm wide at the bottom,
10 cm wide at the top, and converged in an equilateral
triangular central area. The procedure was similar to
that described previously [21]: each mouse, none of
which had any prior experience with the maze, was
placed at the end of one arm and allowed to move freely
through the maze during an 8-min session, and arm
entries were counted. Each series of arm entries was
recorded visually, and an arm entry was defined as
when the hind paws of the mouse were completely
within the arm. Alternation was defined as successive
entries into the three arms in overlapping triplet sets.
The percentage alternation was calculated using the fol-
lowing formula:
number of alternations
totaln umber of arm entries − 2
× 100%
Novel object recognition test
The novel object recognition test, which was described
previously [22], was used with some modifications.
The apparatus consisted of a wooden open-field box
(30 × 30 × 35 cm high). The task was divided into
three different sessions (the habituation, familiariza-
tion, and retention sessions) and carried out for three
consecutive days. On the first and second days, the
mice were habituated to the experimental conditions
and open-field apparatus without objects for 15 min/
day. On the third day, the mice participated in a 5-min
familiarization session in the presence of two identical
objects (cylindrical columns). The time spent exploring
each object, which was defined as when a mouse
orientated their head toward the object and
approached it (within 1 cm), was assessed manually
using a stopwatch. Immediately after the familiariza-
tion session, the mice were removed from the appara-
tus, and one of the familiar objects was randomly
replaced with a novel object (triangle pole). The mice
were then returned to the apparatus and participated
in a 5-min retention session in the presence of the
familiar object and the novel object. The time spent
exploring the familiar and novel objects was manually
measured for 5 min. Then, an exploratory preference
value was calculated; i.e., the ratio of the amount of
time spent exploring any one of the two familiar
objects (familiarization session) or the novel object
(retention session) over the total time spent exploring
the two types of objects. An exploratory preference of
50% corresponds to chance, and a significantly higher
exploratory preference reflects good recognition
memory.
Real-time RT-PCR
For real-time RT-PCR, mice were sacrificed after the
administration of LPS and/or betaine. Immediately
after their decapitation, their hippocampi were rapidly
dissected according to the method of Glowinski &
Iversen [23] and immersed in liquid nitrogen. Frozen
hippocampi were stored at -80°C until use. Total RNA
was extracted using RNA-Bee Reagent (Tel-Test, Inc.,
Friendswood, TX, USA) according to the manufac-
turer’s instructions, which is an improved version of
the single-step method of RNA isolation [24]. Reverse
transcription was performed with an ExScript RT
reagent Kit (Perfect Real Time) or a PrimeScript RT
reagent Kit (Perfect Real Time) (Takara Bio Inc., Otsu,
Japan) under the conditions recommended by the
manufacturer. Real-time PCR analysis was undertaken
using SYBR Premix Ex Taq or SYBR Premix Ex Taq II
(Takara Bio Inc.). Data collection involved using a
Chromo4 real-time PCR detector and analysis with an
LPS injection (30 μg/mouse, i.c.v.)
Y-maze test Novel object recognition test
-1 0 7 10 12 (days) 11
Administration of betaine (0.081, 0.163 and 
0.326 mmol/kg/day, s.c.) or saline (s.c.)
1
Real time RT-PCR analysis
(A) Experimental schedule of Fig. 2 - 6. 
LPS injection (30 μg/mouse, i.c.v.)
Y-maze test Novel object recognition test
-1 0 7 10 12 (days) 11
Administration of betaine (0.163 mmol/kg, s.c.) 
or saline (s.c.) 1 hr before, 1 and 24 hr after  LPS injection
1
(B) Experimental schedule of Fig. 7. 
LPS injection (30 μg/mouse, i.c.v.)
Y-maze test
-1 0 7 (days)
Administration of betaine (0.163 mmol/kg, s.c.) 
or saline (s.c.) 1 hr before or after LPS injection
1
(C) Experimental schedule of Fig. 8. 
Figure 1 Experimental schedules.
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cules, CA, USA). The real-time PCR primers used in
this study are listed in Table 1. All primers were pur-
chased from Takara Bio Inc. The real-time PCR condi-
tions were as follows: initial denaturation at 95°C for
10 s followed by 40 cycles of 95°C for 5 s and 60°C for
20 s. The expression levels of the genes analyzed by
real-time PCR were quantified by comparison with a
standard curve and normalized relative to levels of ß-
actin.
Data analysis
Statistical analysis was performed, and the figures were
produced using Prism 5 for Mac OS X (GraphPad Soft-
ware, Inc., San Diego, CA, USA). It could not be assumed
that the behavioral data were sampled from a Gaussian
distribution; therefore, the data are expressed as median
and interquartile range values. Significance was evaluated
using the Mann-Whitney U-test for comparisons
between two groups, and Kruskal-Wallis non-parametric
one-way ANOVA followed by Bonferroni’st e s tw e r e
used for multiple comparisons. The expression levels of
each mRNA are shown as mean ± S.E.M. An unpaired t-
test (also with Welch-correction when F-test was signifi-
cant) was used to compare two groups, and one-way
ANOVA followed by Dunnett’s test was used for multiple
comparisons. The criterion for significance was p < 0.05.
Results
Effects of repeated administration of betaine on LPS-
induced memory impairment
In the Y-maze test, LPS treatment (30 μg/mouse, i.c.v.)
significantly decreased the percentage of alternations 7
days after LPS injection (Mann-Whitney U-test, p <
0.05, U = 17.00, Figure 2A) without changing the total
number of arm entries (Mann-Whitney U-test, p =
0.199, U = 25.50, Figure 2B). Repeated administration of
betaine showed a bell-shaped dose-response relationship,
and a dose of 0.163 mmol/kg (s.c.) significantly reversed
the LPS-induced impairment of spontaneous alterna-
tions (Bonferroni’s test, p < 0.05, Figure 2A) without
changing the total number of arm entries (Kruskal-
Wallis non-parametric ANOVA, H(3) = 2.021, p =
0.568, Figure 2B).
In the novel object recognition test, there was a
decrease in preference for the novel object (Mann-Whit-
ney U-test, p < 0.01, U = 11.00, Figure 2D) without any
changes in exploratory behavior during the familiariza-
tion session (Exploratory preference: Mann-Whitney U-
test, p = 0.222, U = 26.00, Figure 2C; Total exploratory
time: Mann-Whitney U-test, p = 0.610, U = 34.00, Table
2) 12 days after injection of LPS (30 μg/mouse).
Repeated administration of betaine also showed a bell-
shaped dose-response relationship, as was shown in the
Y-maze test, and the same dose of betaine (0.163 mmol/
kg) significantly reversed the LPS-induced decrease in
exploratory behavior (Bonferroni’s test, p < 0.05, Figure
2D) without any changes in exploratory behavior during
the familiarization session (Exploratory preference: Krus-
kal-Wallis non-parametric ANOVA, H(3) = 2.033, p =
0.566, Figure 2C; Total exploratory time: Kruskal-Wallis
non-parametric ANOVA, H(3) = 0.4513, p = 0.929,
Table 2).
Effects of betaine on LPS-induced increases in mRNA
expression of proinflammatory molecules
Cytokines and proinflammatory molecules are important
for the pathogenesis of LPS-induced memory impair-
ment. We therefore investigated whether repeated
administration of betaine could prevent LPS-induced
increases in mRNA expression levels for proinflamma-
tory molecules such as IL-1b,T N F - a,i N O S ,a n dC O X -
2. The mRNA expression levels of these inflammatory
molecules transiently increased after LPS injection and
recovered to baseline levels by 24 hr after LPS injection
(Figure 3). LPS treatment (30 μg/mouse) significantly
increased the mRNA expression levels of IL-1b, TNF- a,
iNOS, COX-2, and IL-6 6 hr after LPS injection
(unpaired t-test, p < 0.05 vs. corresponding sham con-
trol group, t = 8.451, 9.591, 3.413, 9.164 and 8.749,
respectively, df = 5, Figure 4). Administration of betaine
Table 1 Gene-specific real time RT-PCR primer sequences.
Gene Sequence (5’-3’)
ß-actin forward TGACAGGATGCAGAAGGAGA
reverse GCTGGAAGGTGGACAGTGAG
CD11b forward TCACCCTCAAGGGCAACCTATC
reverse AGGGCAAACGCAGAGTCATTAAAC
CD45 forward TCCCAGCAGACAGGGTTGTTC
reverse GTCCATTCTGGGCGGGATAG
COX-2 forward GTGTGCGACATACTCAAGCAGGA
reverse TGAAGTGGTAACCGCTCAGGTG
GAT2 forward CCATCTTGGGCTTCATGTCTCA
reverse CAGCTGGGACAAAGGCATCA
GFAP forward ACCAGCTTACGGCCAACAGTG
reverse TGTCTATACGCAGCCAGGTTGTTC
IL-1ß forward TCCAGGATGAGGACATGAGCAC
reverse GAACGTCACACACCAGCAGGTTA
IL-6 forward CCACTTCACAAGTCGGAGGCTTA
reverse GCAAGTGCATCATCGTTGTTCATAC
iNOS forward GGAATGGAGACTGTCCCAGCA
reverse GTCATGAGCAAAGGCGCAGA
Heme oxygenase-1 forward TGCAGGTGATGCTGACAGAGG
reverse TGTCTGGGATGAGCTAGTGCTGA
TNF-a forward AAGCCTGTAGCCCACGTCGTA
reverse GGCACCACTAGTTGGTTGTCTTTG
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Page 4 of 13(0.081 and 0.163 mmol/kg) did not prevent the LPS-
induced increases in the levels of these mRNAs (one-
way ANOVA; IL-1b:F 2, 15 = 2.535, p = 0.113; TNF- a:
F2, 15 =0 . 0 3 0 8 ,p=0 . 9 7 0 ;i N O S :F 2, 15 = 0.8014, p =
0.467; COX-2: F2, 15 = 0.0228, p = 0.978; IL-6: F2, 15 =
0.0009, p = 0.999; Figure 4). The mRNA expression
level of heme oxygenase-1, a known marker of oxidative
stress, was also significantly increased 6 hr after LPS
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Figure 2 Effects of repeated administration of betaine on LPS-induced memory impairment. Y-maze and novel object recognition tests
were carried out 7 and 10-12 days after LPS injection (30 μg/mouse, i.c.v.), respectively. The mice were continuously treated with betaine (0.081,
0.163 and 0.326 mmol/kg, s.c.) for 13 days starting 1 day before LPS injection. On the day of the Y-maze and novel object recognition tests,
betaine was administered 30 min before the test. Y-maze data (A: % alternation, B: total arm entries) are shown as the median (vertical column)
and as the first and third quartile values (vertical line). Novel object recognition data (C: familiarization session, D: retention session) are shown as
the median (horizontal bar) and as the first and third quartile values (vertical column). The number of mice used is shown in parentheses.
Significance levels: *p < 0.05, **p < 0.01 vs. sham control (Mann-Whitney’s U-test), and #p < 0.05 vs. LPS alone (Bonferroni’s test).
Table 2 Total exploratory time in the familiar session.
Treatment N Total exploratory time (sec) (range)
Sham control 9 10.73 (7.865 - 11.66)
LPS (30 μg/mouse, i.c.v.) 9 9.980 (6.980 - 12.12)
LPS (30 μg/mouse, i.c.v.) + betaine (0.081 mmol/kg, s.c.) 8 10.94 (7.128 - 12.43)
LPS (30 μg/mouse, i.c.v.) + betaine (0.163 mmol/kg, s.c.) 9 10.24 (6.295 - 11.99)
LPS (30 μg/mouse, i.c.v.) + betaine (0.326 mmol/kg, s.c.) 8 9.325 (7.215 - 10.75)
See Fig. 2 for details.
Miwa et al. Journal of Neuroinflammation 2011, 8:153
http://www.jneuroinflammation.com/content/8/1/153
Page 5 of 13injection (unpaired t-test, p < 0.05; Sham control group:
1.000 ± 0.084, n = 4; LPS group: 3.688 ± 0.520, n = 4,
Welch-corrected t = 5.101, df = 3), and betaine treat-
ment (0.163 mmol/kg) did not prevent this increase
(unpaired t-test, p = 0.961, t = 0.0508, df = 7; LPS
group: 3.688 ± 0.520, n = 4; LPS + betaine group: 3.730
± 0.608, n = 5).
Effects of betaine on LPS-induced increases in mRNA
expression levels of glial markers and the betaine
transporter
Glial activation is also involved in the pathogenesis of
LPS-induced memory impairment; therefore, to under-
stand the effects of betaine on these cells, LPS-induced
increases in mRNA expression levels for CD11b and
CD45, which are microglial markers, and glial fibrillary
acidic protein (GFAP), a marker of astrocytes, were
investigated. LPS treatment (30 μg/mouse) significantly
increased mRNA expression levels of CD11b, CD45, and
GFAP 24 hr after injection (unpaired t-test, p < 0.01, t =
4.425, df = 14 for CD11b; Welch-corrected t = 5.083, df
= 7 for CD45; Welch-corrected t = 7.528, df = 8 for
GFAP, Figure 5); however, betaine treatment (0.163
mmol/kg) did not prevent LPS-induced increases in
mRNA levels of these glial markers (unpaired t-test, p =
0.5603, df = 14 for CD11b; p = 0.9085, df = 14 for
CD45; t = 0.3956, df = 14 for GFAP, Figure 5).
Betaine may act on GAT2/BGT-1 expressed in neu-
rons and/or glial cells to improve memory impairment;
therefore, we examined the effects of LPS and betaine
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Figure 3 LPS-induced changes in levels of mRNA related to inflammation in the hippocampus. Time-dependent changes in mRNA
expression levels for IL-1b, TNF-a, iNOS, and COX-2 in hippocampus after LPS injection are shown in figures (A), (B), (C), and (D), respectively.
LPS (30 μg/mouse, i.c.v.) or saline was injected into the lateral ventricle of each mouse. The mice were sacrificed 1.5, 3, 6, 9, or 24 hr after LPS
injection. Their mRNA levels were assessed by real-time RT-PCR. Each mRNA level was normalized to the mRNA level of b-actin as an
endogenous control. Values are shown as the mean ± S.E.M. for 3-5 mice, as shown in parentheses. Significance levels: *p < 0.05, **p < 0.01 vs.
corresponding sham control (unpaired t-test).
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Figure 4 Effects of betaine on LPS-induced increases in the levels of mRNA related to inflammation.M i c ew e r et r e a t e dw i t hb e t a i n e
(0.081 and 0.163 mmol/kg, s.c.) 24 hr before and immediately before LPS injection (30 μg/mouse, i.c.v.), and sacrificed 6 hr after LPS injection.
mRNA levels in hippocampus were assessed by real-time RT-PCR. The level of each mRNA was normalized to the mRNA level of b-actin as an
endogenous control. Values are shown as the mean ± S.E.M. for 6 mice, as shown in parentheses. Significance levels: *p < 0.05, **p < 0.01 vs.
sham control (unpaired t-test).
Miwa et al. Journal of Neuroinflammation 2011, 8:153
http://www.jneuroinflammation.com/content/8/1/153
Page 7 of 130 6 9 24 48
0
2
4
6
8
10 Sham control (n=4-6)
LPS (n=4-5)
**
*
Time after administration (hr)
C
D
1
1
b
 
/
 
ß
-
a
c
t
i
n
0 6 9 24 48
0
5
10
15
20 Sham control (n=4-6)
LPS (n=4-5)
*
*
Time after administration (hr)
C
D
4
5
 
/
 
ß
-
a
c
t
i
n
0 6 9 24 48
0
2
4
8
6
Sham control (n=4-6)
LPS (n=4-5)
*
*
*
Time after administration (hr)
G
F
A
P
 
/
 
ß
-
a
c
t
i
n
0
1
2
3
4
**
Sham 
control LPS (30 μg/mouse, i.c.v.)
(8) (8) (8)
Betaine (0.163 mmol/kg, s.c.)
C
D
1
1
b
 
/
 
ß
-
a
c
t
i
n
0
2
4
6
8
**
Sham 
control LPS (30 μg/mouse, i.c.v.)
(8) (8) (8)
Betaine (0.163 mmol/kg, s.c.)
C
D
4
5
 
/
 
ß
-
a
c
t
i
n
0
2
4
6
8
Sham 
control LPS (30 μg/mouse, i.c.v.)
(8) (8) (8)
Betaine (0.163 mmol/kg, s.c.)
**
G
F
A
P
 
/
 
ß
-
a
c
t
i
n
(A)
(D) (C)
(B)
(E) (F)
Figure 5 Effects of betaine on LPS-induced increases in mRNA expression levels for glial markers. Time-dependent changes in mRNA
expression levels for CD11b, CD45, and GFAP in hippocampus 6, 9, 24, and 48 hr after LPS injection (30 μg/mouse, i.c.v.) are shown in figures
(A), (C), and (E), respectively. The mice were treated with betaine (0.163 mmol/kg, s.c.) 24 hr before and immediately before LPS injection (30 μg/
mouse, i.c.v.), and sacrificed 24 hr after LPS injection. mRNA levels in hippocampus were assessed by real-time RT-PCR. The level of each mRNA
was normalized to the mRNA level of b-actin as an endogenous control. Values are shown as the mean ± S.E.M. for 4-8 mice, as shown in
parentheses. Significance levels: *p < 0.05, **p < 0.01 vs. corresponding sham control (unpaired t-test).
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Page 8 of 13on mRNA expression for GAT2. LPS treatment (30 μg/
mouse) significantly increased mRNA expression for
GAT2 24 hr after injection (unpaired t-test, p < 0.05,
Welch-corrected t = 3.489, df = 6, Figure 6A, B). Inter-
estingly, betaine (0.163 mmol/kg) prevented this LPS-
induced increase in GAT2 mRNA levels (unpaired t-
test, p < 0.05, t = 2.301, df = 12, Figure 6B). These
results may indicate that repeated administration of
betaine is not necessary to prevent LPS-induced mem-
ory impairment. Therefore, as our next experiment, we
conducted behavioral experiments after subacute (1 hr
before, 1 and 24 hr after LPS injection) or acute (1 hr
before or after LPS injection) administration of betaine.
Effects of subacute administration of betaine on LPS-
induced memory impairment
LPS treatment (30 μg/mouse) significantly decreased the
percentage of alternations in the Y-maze test (Mann-
Whitney U-test, p < 0.01, U = 59.0, Figure 7A) and the
degree of preference for the novel object (Mann-Whit-
ney U-test, p < 0.01, U = 58.0, Figure 7D). Subacute
administration of betaine (0.163 mmol/kg) significantly
reversed LPS-induced memory impairment in the Y-
maze (Mann-Whitney U-test, p < 0.01, U = 64.0, Figure
7A) and novel object recognition tests (Mann-Whitney
U-test, p < 0.05, U = 70.0, Figure 7D). These treatments
had no influences on the total number of arm entries in
the Y-maze test (Figure 7B) or on exploratory behavior
during the familiarization session in the novel object
recognition test (Figure 7C, Table 3).
Effects of acute administration of betaine on LPS-induced
memory impairment
We further examined whether a single administration of
b e t a i n ei sa b l et op r e v e n tL P S - i n d u c e dm e m o r yi m p a i r -
ment (experimental schedule shown in Figure 1C).
Interestingly, a single administration of betaine (0.163
mmol/kg) 1 hr after LPS injection also significantly
reversed LPS-induced impairment of spontaneous alter-
nation (Mann-Whitney U-test, p < 0.05, U = 29.5, Fig-
ure 8A); however, a single administration of betaine 1
hr before LPS injection did not reverse LPS-induced
impairment of spontaneous alternation (Mann-Whitney
U-test, p = 0.795, U = 67.0, Figure 8A).
Discussion
It has been reported that betaine suppresses expression
of proinflammatory molecules such as COX-2, iNOS,
and TNF- a; and increases oxidative stress in aged rat
kidney [6,7]. Betaine also prevents chronic ethanol con-
sumption-induced oxidative stress in brain synapto-
somes [25]. These reports suggest that betaine might be
a useful compound for preventing neurodegenerative
disorders and/or other diseases involving inflammatory
processes and oxidative stress; however, the effects of
betaine on memory impairment involving neuroinflam-
matory and/or oxidative stress are not well known.
Therefore, the effects of betaine on LPS-induced mem-
ory impairment were evaluated. Repeated administration
of betaine (0.163 mmol/kg) improved LPS-induced
memory impairment in the Y-maze and novel object
recognition tests, with a bell-shaped dose-response
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Figure 6 Effects of betaine on LPS-induced increases in mRNA
expression levels for GAT2. Time-dependent changes in GAT2
mRNA expression in hippocampus 6, 9, 24, and 48 hr after LPS
injection (30 μg/mouse, i.c.v.) are shown in the upper panel (A).
Mice were treated with betaine (0.163 mmol/kg, s.c.) 24 hr before
and immediately before LPS injection (30 μg/mouse, i.c.v.), and
sacrificed 24 hr after LPS injection. mRNA levels in hippocampus
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parentheses. Significance levels: *p < 0.05 vs. sham control, #p <
0.05 vs. LPS alone (unpaired t-test).
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Page 9 of 13relationship. Our findings suggest that betaine improves
LPS-induced memory impairment, but it is possible that
the preference for the object changed due to some per-
ceptual effects rather than memory effects, and/or
induction of sickness behavior may have changed the
innate preference for an object without affecting mem-
ory processes. However, we used identical objects in the
familiarization sessions, after which one of these objects
was randomly replaced with a novel object. Further,
sickness behavior is usually assessed within 24 hr of
induction, but in our protocol the behavioral experi-
ments were conducted 7 to 12 days after LPS injection.
On these days, no sickness-like behavior was seen, as in
other investigations; therefore, we think that the effects
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Figure 7 Effects of subacute administration of betaine on LPS-induced memory impairment. Y-maze and novel object recognition tests
were carried out 7 and 10-12 days after LPS injection (30 μg/mouse, i.c.v.), respectively. Mice were treated with betaine (0.163 mmol/kg, s.c.) 1 hr
before and 1 and 24 hr after LPS injection. Y-maze data (A: % alternation, B: total arm entries) are shown as the median (vertical column) and
the first and third quartile values (vertical line). The novel object recognition data (C: familiarization session, D: retention session) are shown as
the median (horizontal bar) and the first and third quartile values (vertical column). The number of mice used is shown in parentheses.
Significance levels: **p < 0.01 vs. sham control, #p < 0.05, ##p < 0.01 vs. LPS alone (Mann-Whitney’s U-test).
Table 3 Total exploratory time in the familiar session.
Treatment N Total exploratory time (sec) (range)
Sham control 16 8.600 (5.918 - 10.40)
LPS (30 μg/mouse, i.c.v.) 16 7.810 (6.813 - 9.165)
LPS (30 μg/mouse, i.c.v.) + betaine (0.163 mmol/kg, s.c.) 18 8.055 (5.540 - 10.87)
See Fig. 7 for details.
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Page 10 of 13of LPS and/or betaine reflect memory function rather
than other effects. Taken together, these results suggest
that betaine has a preventative effect on LPS-induced
memory impairment caused by neuroinflammatory
responses.
As described in Background, LPS induces expression
of proinflammatory molecules and glial activation within
several days of LPS injection. For example, Szczepanik
& Ringheim [26] reported that i.c.v. injection of LPS
induces production of proinflammatory cytokines such
as IL-1a,I L - 1 b,I L - 6 ,a n dT N F - a in mouse hippocam-
pus and cortex. These increases in the expression levels
of proinflammatory cytokines peaked about 6 - 9 hr
after LPS injection. LPS-induced neuronal injury
requires the presence of microglia and Toll-like receptor
4-dependent pathways [27]. Choi et al. [28] reported
that i.c.v. injection of LPS induces neuronal damage and
activation of microglia and astrocytes in hippocampus
24 hr after LPS injection. Therefore, we investigated
whether betaine could suppress LPS-induced increases
in mRNA expression levels of various proinflammatory
molecules and glial markers in hippocampus concur-
rently with the observed improvements in memory
impairment. LPS induced a transient increase in mRNA
expression levels for IL-1b,T N F -a, iNOS, and COX-2;
and these increases returned to sham-control levels by
24 hr after LPS injection; however, betaine (0.081 or
0.163 mmol/kg) did not affect the LPS-induced increases
in mRNA levels for these inflammatory molecules.
LPS treatment (30 μg/mouse) also increased mRNA
expression levels of the microglial markers CD11b and
CD45, and the astrocytic marker GFAP; however,
betaine also did not prevent the LPS-induced increases
in mRNA levels for these glial markers. Our results indi-
cate that betaine does not suppress mRNA expression of
proinflammatory molecules or glial markers, and the
mechanism behind the ameliorating effects of betaine
on memory impairment is not mediated by the expres-
sion of these genes, which is the mechanism by which
betaine suppresses the expression of proinflammatory
molecules and increased oxidative stress in aged rat kid-
ney [6,7]. This finding indicates that the mechanism
behind the actions of betaine in the central nervous sys-
tem is different from that in kidney.
Four different subtypes of GAT have been cloned and
are termed GAT1, GAT2, GAT3, and GAT4 in mice
(GAT-1, BGT-1, GAT-2 and GAT-3, respectively, in
rats and humans) [29]. GAT2/BGT-1 transports both
GABA and betaine [9,30]. In renal epithelial cells,
GAT2/BGT-1 is a basolateral membrane protein that
protects cells in the hypertonic inner medulla by med-
iating betaine uptake and accumulation [5]. In the cen-
tral nervous system, it has been reported that betaine
content and BGT-1 mRNA levels are increased in brain
of rats with hyperosmotic serum induced by the injec-
tion and drinking of NaCl solution [31,32]. In addition,
protein and mRNA expressions of GAT2/BGT-1 are
upregulated in mouse and rat astrocyte primary cultures
exposed to hyperosmotic conditions [10,33]. These
results suggest that betaine and GAT2/BGT-1 play
important roles in osmotic regulation in the central ner-
vous system. Moreover, expression of BGT-1 is
increased in astrocytes after kainate-induced neuronal
injury in rat hippocampus [11]. While betaine and
GAT2/BGT-1 may be involved in neuronal dysfunction
caused by neurodegeneration or neuronal injury, their
physiological roles are not yet known. In the present
study, we examined mRNA expression for GAT2 after
treatment with LPS and/or betaine in mouse
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Figure 8 Effects of acute administration of betaine on LPS-
induced memory impairment in the Y-maze test. The Y-maze
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Whitney’s U-test).
Miwa et al. Journal of Neuroinflammation 2011, 8:153
http://www.jneuroinflammation.com/content/8/1/153
Page 11 of 13hippocampus. LPS treatment (30 μg/mouse) significantly
increased mRNA expression for GAT2 24 hr after LPS
injection. Interestingly, betaine (0.163 mmol/kg) blocked
this LPS-induced increase in mRNA expression for
GAT2, suggesting that betaine and its transporter,
GAT2/BGT-1, play important roles in neuronal dysfunc-
tion caused by neuronal injury.
It is known that the changes that occur during the
early phase after LPS treatment are crucial to delayed
neuronal impairment such as the memory impairment
shown in this study. To elucidate the mechanisms
underlying the effects of betaine, we considered that
administration of betaine during the early phase after
LPS injection might be necessary for preventing LPS-
induced memory because mRNA expression levels for
GAT2 transiently increased after LPS injection and
recovered by 48 hr after LPS injection. Interestingly,
either subacute (1 hr before, 1 and 24 hr after the LPS
injection) or single (1 hr after the LPS injection) admin-
istration of betaine prevented LPS-induced memory
impairment, but this effect was not seen when betaine
was given 1 hr before LPS injection. Consistent with
betaine’s effect in alleviating LPS-induced delayed mem-
ory impairment, betaine also significantly reduced LPS-
induced increases in GAT2 mRNA levels in hippocam-
pus. These data suggest that during the early period
after LPS injection, betaine plays a crucial role in pre-
venting LPS-induced neuronal dysfunction. On the
other hand, a single administration of betaine, 1 hr
before LPS injection, did not prevent LPS-induced
memory impairment. This finding that betaine has a
neuroprotective effect on delayed memory impairment
even when administered after LPS injection has impor-
tant therapeutic implications. Excitotoxicity has been
i m p l i c a t e di nt h ee t i o l o g yo fi s c h e m i cs t r o k ea n d
chronic neurodegenerative disorders. Hence, the devel-
opment of novel neuroprotective molecules that amelio-
rate excitotoxic brain damage is being vigorously
pursued. Indeed, betaine attenuates glutamate-induced
neurotoxicity in primary cultured brain cells [34]. Mon-
toliu et al. [35] reported that a family of trialkylglycines
significantly prevent excitotoxic neuronal death in mod-
els of neurodegeneration. Since dietary and supplemen-
tary administration of betaine has been studied in
humans, if the detailed mechanism of betaine could be
clarified, it could become a candidate for treatment of
cognitive dysfunction in disorders such as Alzheimer’s
disease and senile dementia.
Conclusions
Betaine improves LPS-induced memory impairment and
blocks LPS-induced increases in mRNA expression for
GAT2; however, betaine does not prevent LPS-induced
increases in mRNA expression of proinflammatory
molecules or glial markers. These results suggest that
betaine has protective effects against LPS-induced mem-
ory impairment that are mediated through unique
mechanisms involving betaine actions on GAT2, which
is involved in the development of memory impairment,
without affecting proinflammatory molecules or glial
markers.
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